利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.043 秒)

    Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
    21.
    发明授权
    Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes 有权
    通过添加αGal表位增强肿瘤相关抗原的免疫原性

    公开(公告)号：US07998486B2

    公开(公告)日：2011-08-16

    申请号：US11977203

    申请日：2007-10-24

    申请人： Mario R. Mautino ,  Nicholas N. Vahanian ,  Won-Bin Young ,  Gabriela Rossi ,  Charles J. Link ,  Firoz Jaipuri

    发明人： Mario R. Mautino ,  Nicholas N. Vahanian ,  Won-Bin Young ,  Gabriela Rossi ,  Charles J. Link ,  Firoz Jaipuri

    IPC分类号： A61K38/00

    CPC分类号： C07H5/04 ,  A61K31/70 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55511 ,  C07H15/00 ,  C07H15/04

    摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

    摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变​​以引入αGal表位或αGal糖模拟表位，以允许通过以下方式增强抗原的调理作用 天然抗αGal抗体刺激TAA捕获和表达，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。

    Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
    23.
    发明授权
    Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase 失效
    基于N-乙酰乳糖苷酶3-α半乳糖基转移酶表达的可选基因标记系统

    公开(公告)号：US07078179B2

    公开(公告)日：2006-07-18

    申请号：US10838750

    申请日：2004-05-04

    申请人： Teresa Di Colandrea ,  Cherisa Meyer ,  Won-Bin Young ,  James N. Higginbotham ,  Mario Mautino ,  Charles J. Link, Jr.

    发明人： Teresa Di Colandrea ,  Cherisa Meyer ,  Won-Bin Young ,  James N. Higginbotham ,  Mario Mautino ,  Charles J. Link, Jr.

    IPC分类号： G01N33/567 ,  G01N33/53 ,  C12Q1/68 ,  C12N15/63 ,  C12N15/86

    CPC分类号： G01N33/5023 ,  C07K16/40 ,  C07K2317/11 ,  C07K2317/23 ,  C12N9/1051 ,  C12N2799/027 ,  G01N2333/91102

    摘要： A method is described for the rapid identification and isolation of cells based on the presence or absence of an ectopically-expressed N-acetyllactosaminide 3-α Galactosyltransferase (αGT) enzyme for the production of αGalactosyl-(1,3)Galactosyl (αGal) epitopes on the surface of αGal-negative cells. These cells which are genetically modified to express the αGT enzyme and αGal epitopes on glycosylated lipids and proteins of the cell surface are then labeled via an antibody composition which recognizes and binds the αGal epitopes on the cell surface. Cells labeled with the anti-αGal antibody can be isolated by sorting via fluorescence activated cell sorting (FACS), or by magnetic panning techniques. This method is suitable for the rapid positive or negative selection of αGal-positive cells from within a population of αGal-negative cells without the need to expose cells to antibiotics for any period of time. In addition, the specification provides a method for the production and purification of anti-αGal antibodies from chicken egg yolk.

    摘要翻译： 描述了用于快速鉴定和分离细胞的方法，所述方法基于是否存在用于产生α-半乳糖基 - （1,3）半乳糖基（αGal）表位的异位表达的N-乙酰乳糖苷酶3-α半乳糖转移酶（αGT） 在αGal阴性细胞的表面。 然后通过识别和结合细胞表面上的αGal表位的抗体组合物来标记经遗传修饰以表达糖基化脂质和细胞表面蛋白质上的αGT表位的这些细胞。 用抗αGal抗体标记的细胞可以通过荧光激活细胞分选（FACS）进行分选，或通过磁性淘选技术分离。 该方法适用于从αGal阴性细胞群体内快速阳性或阴性选择αGal阳性细胞，无需在任何时间段内将细胞暴露于抗生素。 此外，本说明书提供了从鸡蛋黄制备和纯化抗αGal抗体的方法。

    Fused imidazole derivatives useful as IDO inhibitors
    27.
    发明授权
    Fused imidazole derivatives useful as IDO inhibitors 有权
    用作IDO抑制剂的熔融咪唑衍生物

    公开(公告)号：US09260434B2

    公开(公告)日：2016-02-16

    申请号：US14053440

    申请日：2013-10-14

    申请人： NewLink Genetics Corporation

    发明人： Mario Mautino ,  Sanjeev Kumar ,  Jesse Waldo ,  Firoz Jaipuri ,  Tanay Kesharwani ,  Xiaoxia Zhang

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04 ,  C07F9/6561

    摘要： Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

    摘要翻译： 目前提供的是可用于调节吲哚胺2,3-双加氧酶活性的IDO抑制剂及其药物组合物; 治疗吲哚胺2,3-双加氧酶（IDO）介导的免疫抑制; 治疗受抑制吲哚胺-2,3-双加氧酶酶活性的医学病症; 提高抗癌治疗的有效性，包括施用抗癌剂; 治疗与癌症有关的肿瘤特异性免疫抑制; 并治疗与感染性疾病相关的免疫抑制。

    Imidazole derivatives as IDO inhibitors
    28.
    发明授权
    Imidazole derivatives as IDO inhibitors 有权
    咪唑衍生物作为IDO抑制剂

    公开(公告)号：US08722720B2

    公开(公告)日：2014-05-13

    申请号：US13501633

    申请日：2010-10-27

    申请人： Mario R. Mautino ,  Sanjeev Kumar ,  Firoz Jaipuri ,  Jesse Waldo ,  Tanay Kesharwani

    发明人： Mario R. Mautino ,  Sanjeev Kumar ,  Firoz Jaipuri ,  Jesse Waldo ,  Tanay Kesharwani

    IPC分类号： A61K31/4174 ,  C07D233/64

    CPC分类号： C07D233/64 ,  C07D401/12 ,  C07D403/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

    摘要： Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

    摘要翻译： 目前提供的如下所示的通式（VII），（VIII）的IDO抑制剂及其药物组合物，其可用于调节吲哚胺2,3-双加氧酶的活性; 治疗吲哚胺2,3-双加氧酶（IDO）介导的免疫抑制; 治疗受抑制吲哚胺-2,3-双加氧酶酶活性的医学病症; 提高抗癌治疗的有效性，包括施用抗癌剂; 治疗与癌症有关的肿瘤特异性免疫抑制; 并治疗与感染性疾病相关的免疫抑制。

    Fused Imidazole Derivatives Useful as IDO Inhibitors
    29.
    发明申请
    Fused Imidazole Derivatives Useful as IDO Inhibitors 有权
    用作IDO抑制剂的熔融咪唑衍生物

    公开(公告)号：US20140066625A1

    公开(公告)日：2014-03-06

    申请号：US14053440

    申请日：2013-10-14

    申请人： NewLink Genetics Corporation

    发明人： Mario Mautino ,  Sanjeev Kumar ,  Jesse Waldo ,  Firoz Jaipuri ,  Tanay Kesharwani ,  Xiaoxia Zhang

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04 ,  C07F9/6561

    摘要： Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleanine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

    摘要翻译： 目前提供的是可用于调节吲哚胺2,3-双加氧酶活性的IDO抑制剂及其药物组合物; 治疗吲哚嗪2,3-双加氧酶（IDO）介导的免疫抑制; 治疗受抑制吲哚胺-2,3-双加氧酶酶活性的医学病症; 提高抗癌治疗的有效性，包括施用抗癌剂; 治疗与癌症有关的肿瘤特异性免疫抑制; 并治疗与感染性疾病相关的免疫抑制。